These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 19167601)

  • 1. Adherence to guidelines for use of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia: results of a retrospective study of an electronic medical-records database in the United States, 2002-2006.
    Luo W; Nordstrom BL; Fraeman K; Nordyke R; Ranganathan G; Linz HE; Winterkorn A; Stokes M; Ross SD; Knopf K
    Clin Ther; 2008 Dec; 30(12):2423-35. PubMed ID: 19167601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.
    Nordstrom BL; Luo W; Fraeman K; Whyte JL; Nordyke RJ
    J Manag Care Pharm; 2008; 14(9):858-69. PubMed ID: 19006442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utilization of darbepoetin alfa in relation to cancer patients' hemoglobin levels.
    Hess G; Hill J; Clough J; Hulnick S; Nordyke RJ
    Curr Med Res Opin; 2008 Mar; 24(3):815-9. PubMed ID: 18257979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007.
    Wu Y; Aravind S; Ranganathan G; Martin A; Nalysnyk L
    Clin Ther; 2009; 31 Pt 2():2416-32. PubMed ID: 20110050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in the use of erythropoiesis-stimulating agents (ESAs) and red blood cell transfusion in patients with cancer amidst regulatory and reimbursement changes.
    Gawade PL; Berlin JA; Henry DH; Tomita D; Brooks BD; Franklin J; Bradbury BD; Critchlow CW
    Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1357-1366. PubMed ID: 28809079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit.
    Brophy GM; Sheehan V; Shapiro MJ; Lottenberg L; Scarlata D; Audhya P;
    Clin Ther; 2008 Dec; 30(12):2324-34. PubMed ID: 19167591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
    Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
    Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transfusions increase with nationally driven reimbursement changes of erythropoiesis stimulating agents for chemotherapy-induced anemia.
    Yu JM; Shord SS; Cuellar S
    J Oncol Pharm Pract; 2011 Dec; 17(4):360-5. PubMed ID: 20826550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of anemia in advanced breast and lung cancer patients in daily practice: results of a French survey.
    Ray-Coquard I; Morère JF; Scotté F; Cals L; Antoine EC
    Adv Ther; 2012 Feb; 29(2):124-33. PubMed ID: 22314432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)?
    Bormanis J; Quirt I; Chang J; Kouroukis CT; MacDonald D; Melosky B; Verma S; Couture F
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):132-9. PubMed ID: 23357249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in anemia treatment among patients with five non-myeloid malignancies treated with chemotherapy in a large integrated health care delivery system in California, 2000-2013.
    Xu L; Xu H; Cannavale K; Sattayapiwat O; Rodriguez R; Page JH; Chao C
    Support Care Cancer; 2016 Jul; 24(7):2989-98. PubMed ID: 26872791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemoglobin decline in chemotherapy patients prior to and after policy changes affecting use of erythropoiesis-stimulating agents: 2006-2009.
    Hill JW; Cong Z; Hess G; McGarvey N; Nordyke RJ
    J Int Med Res; 2012; 40(4):1532-45. PubMed ID: 22971506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reassessments of ESAs for cancer treatment in the US and Europe.
    Bennett CL; McKoy JM; Henke M; Silver SM; MacDougall IC; Birgegård G; Luminari S; Casadevall N; Schellekens H; Sartor O; Lai SY; Armitage JO
    Oncology (Williston Park); 2010 Mar; 24(3):260-8. PubMed ID: 20394138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling of treatment response to erythropoiesis-stimulating agents as a function of center- and patient-related variables: results from the Anemia Cancer Treatment (ACT) study.
    Aapro M; Ludwig H; Bokemeyer C; MacDonald K; Soubeyran P; Turner M; Albrecht T; Abraham I
    Ann Oncol; 2009 Oct; 20(10):1714-21. PubMed ID: 19570966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of erythropoiesis-stimulating agents on the short-term and long-term survivals in metastatic breast cancer patients receiving chemotherapy: a SEER population-based study.
    Lai Y; Ye Z; Civan JM; Wang C; Cristofanilli M; Mu Z; Austin L; Palazzo JP; Myers RE; Yang H
    Breast Cancer Res Treat; 2015 Sep; 153(2):407-16. PubMed ID: 26264468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses.
    Vansteenkiste J; Glaspy J; Henry D; Ludwig H; Pirker R; Tomita D; Collins H; Crawford J
    Lung Cancer; 2012 Jun; 76(3):478-85. PubMed ID: 22277104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.
    Nurko S; Spirko R; Law A; Dennis VW
    Clin Ther; 2007 Sep; 29(9):2010-21. PubMed ID: 18035200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia.
    Hoque S; Chen BJ; Schoen MW; Carson KR; Keller J; Witherspoon BJ; Knopf KB; Yang YT; Schooley B; Nabhan C; Sartor O; Yarnold PR; Ray P; Bobolts L; Hrushesky WJ; Dickson M; Bennett CL
    PLoS One; 2020; 15(6):e0234541. PubMed ID: 32584835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease.
    Kim SM; Kim KM; Kwon SK; Kim HY
    J Korean Med Sci; 2016 Jan; 31(1):55-60. PubMed ID: 26770038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.